ellette
Uploaded by
24 SLIDES
455 VUES
250LIKES

Atrial Fibrillation in Patients With Renal Impairment

DESCRIPTION

Atrial Fibrillation in Patients With Renal Impairment. NOACs to Prevent Stroke in NVAF and Renal Impairment. Which NOACs Rely Most on Renal Clearance?. NOAC Dose Reductions (SPAF). Evidence for Using NOACs in Patients With Kidney Disease. Renal Impairment Is Common Among AF Patients.

1 / 24

Télécharger la présentation

Atrial Fibrillation in Patients With Renal Impairment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Atrial Fibrillation in Patients With Renal Impairment

  2. NOACs to Prevent Stroke in NVAF and Renal Impairment

  3. Which NOACs Rely Most on Renal Clearance?

  4. NOAC Dose Reductions (SPAF)

  5. Evidence for Using NOACs in Patients With Kidney Disease

  6. Renal Impairment Is Common Among AF Patients

  7. NOAC Outcomes in NVAF Patients With Moderate Renal Insufficiency

  8. Renal Function Declines Faster With VKA Exposure

  9. Detrimental Effects of VKA on Renal Function

  10. All Agents Impact Renal Function Decline

  11. NOAC Outcomes in NVAF Patients With Worsening Renal Function

  12. Guidance for Use of NOACs in AF and CKD

  13. NOACs in NVAF and Severe Kidney Disease

  14. In Summary

  15. NOACs vs VKAs in Patients With Atrial Fibrillation

  16. RELOAD: Renal Impairment Sub-Analysis

  17. Primary Effectiveness and Safety Outcomes

  18. RELOADED Study

  19. NOACs Showed Significant Risk Reductions for ESRD/Dialysis Rivaroxaban vs Phenprocoumon

  20. NOACs Showed Significant Risk Reductions for ESRD/Dialysis: Apixaban vs Phenprocoumon

  21. Management of AF in Patients With Renal Impairment Concluding Remarks

  22. Abbreviations

  23. Abbreviations (cont)

More Related